COMP <GO>
BMY vs ABBV // FORWARD P/E MULTIPLE
Bristol-Myers Squibb Company (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: BMY 7
— ABBV 7
▲ FORWARD P/E MULTIPLE LEADER: BMY
LAST: $62.48 (+1.78%) • MKT CAP: $125.40B
forward-pe
16.6x
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BMY VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BMY | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 71.10% | 70.20% | +0.90 | BMY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.30% | 29.00% | -15.70 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 16.3x | 33.3x | -17.00 | BMY | /valuation <GO> |
| Free Cash Flow Yield | 10.24% | 3.47% | +6.77 | BMY | /fcf-yield <GO> |
| Operating Margin | 17.90% | 24.60% | -6.70 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 14.60% | 6.90% | +7.70 | BMY | /net-margins <GO> |
| Revenue Growth (YoY) | -0.20% | 8.60% | -8.80 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 4.02% | 2.27% | +1.75 | BMY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.24 | 5.33 | -3.09 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 7.40% | -0.60 | BMY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.7 | 72.8 | -18.07 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 1.15 | -0.17 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 16.6x | 113.1x | -96.50 | BMY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $125.40B | $513.86B | -$388.46B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BMY REV | ABBV REV | BMY GROSS % | ABBV GROSS % | BMY FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $48.19B | $61.16B | 71.1% | 70.2% | $12.85B | $17.82B |
| FY 2024 | $48.30B | $56.33B | 71.1% | 70.0% | $13.94B | $17.83B |
| FY 2023 | $45.01B | $54.32B | 44.0% | 44.0% | $11.83B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BMY // BETA 0.98
ABBV // BETA 1.15